Volume
5, No. 8 August,
2024
p
ISSN 2723-6927-e ISSN 2723-4339
Dyslipidemia And Hypertension Among Indonesian Hajj Pilgrims: A
Cross-Sectional Study
Meity Ardiana1*,
Wira Nirwana2
Department of
Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga,
Indonesia1*2
Email:
Meityardiana@fk.unair.ac.id*
ABSTRACT
There has
been an increase in the prevalence of cardiovascular disease in Indonesia due
to an increased prevalence of hypertension. Cardiovascular disease is the
primary cause of morbidity and mortality among Indonesian Hajj pilgrims. Dyslipidemia and hypertension are positively correlated,
with dyslipidemia potentially contributing to
hypertension through the mechanism of atherosclerosis. The primary objective of
this study is to identify the association between hypertension and dyslipidemia among Indonesian hajj pilgrims. A cross-sectional study involving
114,069 participants in total. The Indonesian Hajj pilgrims in 2023 were the
research population. Pre-embarkation medical exams were performed by qualified
healthcare professionals, and data were taken from Hajj medical service
records. Using bivariate analysis and the Chi-Square (χ2) test, the
proportions of age and gender were compared between the hypertension and
non-hypertension groups. The relationship between triglyceride, HDL, and LDL
levels and hypertension was determined through logistic regression analysis.
Logistic regression analysis was used to provide a multivariate analysis of the
relationship between dyslipidemia and hypertension.
The hypertension group has an average age of 60.2 + 11.6 years old
(p<0.0001). There was no difference in the effect of gender on hypertension
(p=0.105). HDL, LDL, and Triglyceride serum levels significantly affected the
prevalence of hypertension (p<0.0001). Dyslipidemia
was a risk factor for hypertension with an OR of 1.084 (1.057-1.112) (95% CI). Dyslipidemia is a risk factor for hypertension. Serum
levels of HDL, LDL, and triglycerides affect blood pressure.
Keywords: Hypertension, dyslipidemia, risk
factor, cardiovascular disease
INTRODUCTION
Ischemic
heart disease, stroke, vascular disease, and kidney disease are among the
complications of hypertension, which is accountable for 8.5 million fatalities
annually on a global scale. Between 1990 and 2019, the global population of
hypertension patients aged 30-79 years has doubled. Globally, the composition
of the number of people with hypertension consists of 59% women and 41% men. Of
this composition, only 47% of women and 38% of men are treated (Zhou et al., 2021).
In Indonesia,
hypertension in 2018 was 34.1% in the adult population. This number has
increased compared to the prevalence in 2013, which was only 25.8%. The
increasing prevalence of hypertension is a major contributor to cardiovascular
disease in Indonesia (Ri, 2018). Indonesia is a Muslim country
with the largest number of Hajj pilgrims. During Hajj, cardiovascular disease
is the leading cause of morbidity and mortality (Widhidewi, Masyeni, & Pratiwi, 2020).
Abnormalities
in serum cholesterol levels, triglycerides, and lipoproteins are characteristic
of dyslipidemia. Atherosclerotic cardiovascular
disease is associated with elevated serum levels of total cholesterol,
triglycerides, and LDL cholesterol and lower serum levels of HDL cholesterol (Berberich & Hegele, 2022). Hypertension will cause shear
stress on the endothelium, which induces oxidation stress, resulting in
increased lipoprotein permeability in the vascular and the process of
arteriosclerosis.
Hypertension
and dyslipidemia are often related to each other.
Both hypertension and dyslipidemia are risk factors
for vascular damage and cardiovascular disease. Risk factors for cardiovascular
disease and vascular damage include dyslipidemia and
hypertension (Ming Ming Chen et al., 2022). In dyslipidemia,
the interaction between LDL and ROS (Reactive Oxygen Species) will cause
vasoconstriction. Dyslipidemia will also upregulate
AT1 receptors that cause vasoconstriction through the effects of angiotensin II
(Dąbrowska & Narkiewicz, 2023).
RESEARCH METHODS
Study Design and Data Extraction
Data from
Indonesian hajj pilgrims in 2023 was analyzed for
this cross-sectional study. The data were extracted from the medical service
records of Hajj pilgrims, which were examined by trained medical personnel
prior to embarkation. Pre-departure medical examinations were performed at a
hospital or primary care facility. Identities, ages, genders, comorbidities,
and examination results (including systolic and diastolic blood pressure, LDL
cholesterol levels, HDL cholesterol levels, and Triglyceride levels) are among
the data extracted from medical checkup records. A total of 209.782 hajj
pilgrims aged over 18 years were recruited in this study to analyze
the association between dyslipidemia and
hypertension. This study is observational, so it does not require informed
consent.
Study Population
209.782
Indonesian hajj pilgrims in 2023 were the population in this cross-sectional
study. The inclusion criteria in this study were age over 18 years and complete
medical records including identity, age, gender, comorbid diseases, and
examination results of systolic blood pressure, diastolic blood pressure, LDL
cholesterol levels, HDL cholesterol levels, and Triglyceride levels. The
selection of study subjects was divided into two stages. The first stage of
209.782 participants excluded 3.710 participants with incomplete data (age,
sex, comorbid diseases), 25 pregnant women, 26.279 participants with type 2
Diabetes Mellitus, 8.225 participants had cardiovascular disease, 4.892
participants had heart failure, 25 participants had rheumatic heart disease, 513
participants had cardiomyopathy, 140 participants had structural heart disease,
4. 850 participants had arrhythmia, 918 participants had kidney disease, 1.005
participants had cerebrovascular disease, 454 participants had endocrine
disease, 32 participants had systemic lupus erythematous disease, 126
participants had cancer, and 10.491 participants had hyperuricemia. In stage 2
selection, 15.769 participants who did not have blood pressure data, 8.069
participants who did not have LDL level data, and 7.013 participants who did
not have HDL level data were excluded.
Figure 1. The
flowchart selection of participants in the study
Diagnostic Criteria
When systolic
blood pressure exceeds 140 mmHg and/or diastolic blood pressure exceeds 90
mmHg, hypertension is diagnosed. Grade 1 hypertension is determined when the
systolic blood pressure measures are between 140-159 mmHg and/or the diastolic
blood pressure measures are between 90-99 mmHg. Grade 2 hypertension is
determined when the systolic blood pressure measures are between 160 and 179
mmHg and/or the diastolic blood pressure measures are between 100 and 109 mmHg.
Grade 3 hypertension is diagnosed when the systolic blood pressure exceeds 180
mmHg and/or the diastolic blood pressure exceeds 110 mmHg (Williams et al., 2018). A diagnosis of dyslipidemia is proven if any of the following criteria:
HDL values below 40 mg/dl, LDL levels above 160 mg/dl, or triglyceride levels
exceeding 200 mg/dl (Indonesia, 2021).
Statistical Analyses
SPSS Version
26 was used to analyze the data. Bivariate analysis
was conducted using the Chi-Square (χ2) test to examine the relationship
between age, gender, and hypertension status (hypertension or normotension).
The basis for decision-making in the Chi-Square (χ2) test is the
significance value (p-value) less than 0.05 (p-value <0.05). To investigate
the impact of dyslipidemia on the prevalence of
hypertension using age and gender as confounding variables., multivariate
analysis was performed using logistic regression analysis. Odds ratio (OR) and
95% confidence interval (CI) were used to show the results of the multivariate
logistic regression analysis. In logistic regression analysis, the criterion
for decision-making is a significance value (p-value) below 0.05 (p-value
<0.05).
RESULTS AND DISCUSSION
Table 1. Characteristics of Participants based Aged and Gender
Variables |
Hypertension
(n=46.455) |
Non-hypertension
(n=67.614) |
χ2 |
p-value |
Aged (years, mean±sd) |
60,2 ± 11,6 |
52,8 ± 12,7 |
11.994,4 |
<0,0001 |
Age |
6.510,8 |
<0,0001 |
||
18 – 50 years |
9.362 (24,3) |
29.178 (75,7) |
|
|
> 50 years |
37.093 (49,1) |
38.436 (50,9) |
|
|
Gender |
2,623 |
0,105 |
||
Male |
20.631 (41,0) |
29.699 (59,0) |
|
|
Female |
25.824 (40,5) |
37.915 (59,5) |
|
|
The
hypertension group consisted of 46,455 participants, with a median age of 60.2 +
11.6 years. The non-hypertension group consisted of 67,614 participants, with a
median age of 52.8 + 12.7 years. The hypertension group had a higher
average age compared to the non-hypertension group. However, there was no
statistically significant disparity in the prevalence of hypertension between
women and men.
Table 2. Characteristics Participants based Lipid Profiles
Conventional Lipid Profiles |
Total (n=114.069) |
Hypertension (n=46.455) |
Non-hypertension (n=67.614) |
p-value |
1.
HDL (mg/dl,
mean±sd) |
2.
56,92 ±
27,854 |
57,45 ± 28,136 |
56,56 ± 27,653 |
<0,0001 |
3.
LDL (mg/dl,
mean±sd) |
4.
126,21 ±
38,290 |
128,56 ± 39,298 |
124,60 ± 37,497 |
<0,0001 |
5.
Triglycerides
(mg/dl, mean±sd) |
6.
131,52
±64,929 |
136,43 ± 66,111 |
128,15 ± 63,887 |
<0,0001 |
The
hypertension group had higher HDL, LDL, and Triglyceride levels than the
non-hypertension group.
Table 3. Age and gender-based subgroup analysis of lipid profile
differences between hypertension and non-hypertension
Conventional Lipid Profiles |
Hypertension |
Non-hypertension |
p-value |
Hypertension |
Non-hypertension |
p-value |
Age (years) |
< 50 years |
> 50 years |
||||
HDL (mg/dl, mean±sd) |
55.81 ± 28.57 |
55.49 ± 27.37 |
0,001 |
57.86 ± 28.01 |
57.38 ± 27.84 |
<0,0001 |
LDL (mg/dl, mean±sd) |
126.29 ± 37.93 |
121.62 ± 36.34 |
<0,0001 |
129.13 ± 39.61 |
126.86 ± 38.20 |
<0,0001 |
Triglycerides (mg/dl, mean±sd) |
138.7 ± 69.52 |
125.34 ± 65.44 |
<0,0001 |
135.86 ± 65.21 |
130.28 ± 62.60 |
<0,0001 |
Gender |
Male |
Female |
||||
HDL (mg/dl, mean±sd) |
54.98 ± 28.34 |
53.94 ± 28.02 |
<0,0001 |
59.42 ± 27.82 |
58.62 ± 27.19 |
<0,0001 |
LDL (mg/dl, mean±sd) |
125.8 ± 37.98 |
123.05 ± 36.96 |
<0,0001 |
130.77 ± 40.19 |
125.81 ± 37.87 |
<0,0001 |
Triglyceridees (mg/dl, mean±sd) |
142.66 ± 70.29 |
139.1 ± 69.12 |
<0,0001 |
131.46 ± 62.13 |
119.57 ± 58.04 |
<0,0001 |
Both the
under and over 50-year groups have the same characteristics of HDL cholesterol
levels between hypertension and non-hypertension, while LDL cholesterol and
triglyceride levels are higher in hypertension. Based on gender, both men and
women had higher HDL, LDL, and triglyceride levels in the hypertension group
compared to the non-hypertension group.
Correlation Dyslipidemia with
Hypertension Risk
The
prevalence of hypertension was assessed by doing multivariate analysis using
logistic regression analysis to examine the association with dyslipidemia. In logistic regression analysis, the
decision-making criterion is if the significance value (p-value) is below 0.05
(p-value < 0.05). It can be inferred that dyslipidemia
has an association with the prevalence of hypertension.
Table 4. Association of Dyslipidemia and
the risk of Hypertension
Variable |
Hipertension (n=46.455) |
Non-hipertension (n=67.614) |
χ2 |
p-value |
OR1
(95% CI) |
OR2 (95% CI) |
Dyslipidemia |
5,408 |
0,02 |
|
|||
Yes |
18.174 (41,2) |
25.989 (58,8) |
|
|
1,11 (1,083-1,137) |
1,084 (1,057-1,112) |
No |
28.281 (40,5) |
41.625 (59,5) |
|
|
- |
- |
The
number of participants who have dyslipidemia has a
lower prevalence of hypertension when compared to participants who do not have dyslipidemia, with a total of 18,174 people and 28,281
people, respectively. The Chi-Square test findings indicate that the dyslipidemia variable has a significance value (p-value) of
0.02 (p-value <0.05). This suggests a statistically significant association
between dyslipidemia and the prevalence of
hypertension. Furthermore, based on unifactorial logistic regression analysis
or without age and gender as confounding variables, the OR1 (95% CI) value was
1.11 (1.083-1.137). Hypertension risk is increased by dyslipidemia;
the odds ratio is 1.11 times greater in the dyslipidemia
group than in the non-dyslipidemia group.
Additionally, when age and gender were taken as factors that could influence
the results, the multivariate logistic regression analysis showed a higher odds
ratio (OR2) of 1.084 (95% confidence interval: 1.057-1.112). This indicates
that dyslipidemia is a significant risk factor for
hypertension, with the odds of developing hypertension being 1.084 times higher
in the dyslipidemia group compared to the non-dyslipidemia group.
Figure
2. Levels of HDL, LDL, Triglycerides, and various blood pressure levels
This study shows that increased HDL,
LDL, or triglyceride levels will increase blood pressure. An elevation in HDL,
LDL, or triglyceride levels causes an increase in blood pressure. However, an
increase in HDL levels does not correlate proportionally with an increase in
blood pressure. There is a positive correlation between elevated levels of LDL
and Triglycerides and an increase in blood pressure.
Discussion
The
objective of this study is to determine the association between dyslipidemia and hypertension. This study can be concluded
that dyslipidemia increases the risk factor of
hypertension 1.084 times compared to non-dyslipidemia.
Dyslipidemia and hypertension are interrelated. Dyslipidemia can cause hypertension through various
mechanisms, including decreased vascular elasticity due to the process of
atherosclerosis. LDL plays a greater role in the atherosclerosis process
compared to other cholesterol. The process of atherosclerosis begins with LDL
oxidation and internalization into the subendothelial layer. Dyslipidemia also causes endothelial dysfunction, leading
to a decrease in NO production (Haba et al., 2019). Hypertension is
caused by impaired arterial vasodilation. NO plays vasodilatation that occurs
in the arterial endothelium. In dyslipidemia, reduced
NO causes vasoconstriction (Harrison, Coffman, & Wilcox, 2021). Dyslipidemia causes stimulation of LDL into ROS, which
causes the release of eNOS and decreases the amount
of NO production. The decrease in NO production causes peripheral
vasoconstriction (Shaito et al., 2022). Dyslipidemia additionally results in the activation of AT1
receptors, which enhances the vasoconstrictive impact of angiotensin II and
hence raises blood pressure (do Vale et al., 2020).
A
cross-sectional study conducted by Wyszyńska et al. showed that an
increase in LDL and triglycerides had a 5-fold risk of hypertension (Wyszyńska, Łuszczki, Sobek, Mazur, &
Dereń, 2023). In addition,
cross-sectional research conducted by Chen et al. with a study population of
Chinese people showed that high blood pressure was also correlated with
increased triglyceride and LDL levels (Siwei Chen & Cheng, 2022). A study conducted
by Chrusciel et al. revealed a significant correlation between elevated HDL
concentration and systolic blood pressure (Chruściel et al., 2022).
Our
study has several advantages, including a large study population. The study
also excluded confounding variables related to factors that may increase blood
pressure, such as history of heart disease, diabetes, and pregnancy. This study
also shows the characteristics of lipid profiles and blood pressure based on
age and gender. As a cross-sectional study, this research is limited in that it
is unable to establish a causal link between hypertension and dyslipidemia. Furthermore, this study did not examine the
correlation between each lipid profile and elevated systolic or diastolic blood
pressure.
Conclusion
This study
showed that hypertension risk factors are increased in individuals with dyslipidemia. An increase in LDL cholesterol and
triglycerides is proportional to increased blood pressure. High blood pressure
tends to occur in the elderly. No statistically significant disparity was
observed in blood pressure according to gender. Consistent monitoring of blood
pressure and lipid profiles in healthcare facilities is important in this
study. We acknowledge the Department of Cardiology and Vascular Medicine, Faculty
of Medicine, Universitas Airlangga, Indonesia.
References
Berberich, Amanda J.,
& Hegele, Robert A. (2022). A modern approach to dyslipidemia. Endocrine
Reviews, 43(4), 611–653.
Chen, Ming Ming,
Huang, Xuewei, Xu, Chengsheng, Song, Xiao Hui, Liu, Ye Mao, Yao, Dongai, Lu,
Huiming, Wang, Gang, Zhang, Gui Lan, & Chen, Ze. (2022). High remnant
cholesterol level potentiates the development of hypertension. Frontiers in
Endocrinology, 13, 830347.
Chen, Siwei, &
Cheng, Wenke. (2022). Relationship between lipid profiles and hypertension: a
cross-sectional study of 62,957 Chinese adult males. Frontiers in Public
Health, 10, 895499.
Chruściel,
Piotr, Stemplewska, Paulina, Stemplewski, Adam, Wattad, Mohamad, Bielecka-Dąbrowa,
Agata, Maciejewski, Marek, Penson, Peter, Bartlomiejczyk, Marcin A., &
Banach, Maciej. (2022). Associations between the lipid profile and the
development of hypertension in young individuals–the preliminary study. Archives
of Medical Science: AMS, 18(1), 25.
Dąbrowska,
Edyta, & Narkiewicz, Krzysztof. (2023). Hypertension and dyslipidemia: the
two partners in endothelium-related crime. Current Atherosclerosis Reports,
25(9), 605–612.
do Vale, Gabriel T.,
Leoni, Drieli, Sousa, Arthur H., Gonzaga, Natália A., Uliana, Daniela L., La
Gata, Davi C., Resstel, Leonardo B., Padovan, Cláudia M., & Tirapelli,
Carlos R. (2020). Acute restraint stress increases blood pressure and oxidative
stress in the cardiorenal system of rats: a role for AT1 receptors. Stress,
23(3), 328–337.
Haba, Cristian Mihai
Stefan, Mitu, Ovidiu, Al Namat, Razan, Mitu, Ivona, Aursulesei, Viviana, Mitu,
Florin, & Costache, Irina. (2019). Relationship between lipid profile and
blood pressure in hypertensive patients. Journal of Hypertension Research,
5(1), 35–42.
Harrison, David G.,
Coffman, Thomas M., & Wilcox, Christopher S. (2021). Pathophysiology of
hypertension: the mosaic theory and beyond. Circulation Research, 128(7),
847–863.
Indonesia,
Perkumpulan Endokrinologi. (2021). Panduan Pengelolaan Dislipidemia di
Indonesia 2021. Jakarta: PERKENI.
Ri, Kemenkes. (2018).
Laporan Riskesdas 2018 Kementrian Kesehatan Republik Indonesia. Laporan
Nasional Riskesdas, 53(9), 154–165.
Shaito, Abdullah,
Aramouni, Karl, Assaf, Roland, Parenti, Astrid, Orekhov, Alexander, El Yazbi,
Ahmed, Pintus, Gianfranco, & Eid, Ali H. (2022). Oxidative
stress-induced endothelial dysfunction in cardiovascular diseases.
Widhidewi, N. W.,
Masyeni, S., & Pratiwi, A. Eka. (2020). Identification of cardiovascular
risk factors among Hajj pilgrims from Bali in 2018. In Medical Technology
and Environmental Health (pp. 320–324). CRC Press.
Williams, Bryan,
Mancia, Giuseppe, Spiering, Wilko, Agabiti Rosei, Enrico, Azizi, Michel,
Burnier, Michel, Clement, Denis L., Coca, Antonio, De Simone, Giovanni, &
Dominiczak, Anna. (2018). 2018 ESC/ESH Guidelines for the management of
arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Cardiology (ESC) and the European
Society of Hypertension (ESH). European Heart Journal, 39(33),
3021–3104.
Wyszyńska,
Justyna, Łuszczki, Edyta, Sobek, Grzegorz, Mazur, Artur, & Dereń,
Katarzyna. (2023). Association and risk factors for hypertension and
dyslipidemia in young adults from Poland. International Journal of
Environmental Research and Public Health, 20(2), 982.
Zhou, Bin,
Carrillo-Larco, Rodrigo M., Danaei, Goodarz, Riley, Leanne M., Paciorek,
Christopher J., Stevens, Gretchen A., Gregg, Edward W., Bennett, James E.,
Solomon, Bethlehem, & Singleton, Rosie K. (2021). Worldwide trends in
hypertension prevalence and progress in treatment and control from 1990 to
2019: a pooled analysis of 1201 population-representative studies with 104
million participants. The Lancet, 398(10304), 957–980.
Copyright Holder: Meity Ardiana, Wira
Nirwana (2024) |
First Publication
Right: Jurnal
Health Sains |
This article is
licensed under: |